RxDoctor Payments Data

Luis Contreras, MD

Internal Medicine · Brooksville, FLNPI 1790815496

Payments from drug & device makers

$636in general payments, 2019–2025

Across 30 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$156
  • Exact Sciences$64
  • Dexcom, Inc.$54
  • AstraZeneca$44
  • Bayer$44
  • Pfizer$33
  • plus $241 from 12 others

What the payments were for

  • Food & beverage$636100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$261,727
Medicare patients
646
Services billed
2,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$258,757
OzempicSemaglutide93$122,697
JanuviaSitagliptin Phosphate80$97,438
TrulicityDulaglutide38$56,839
XareltoRivaroxaban30$48,014
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$46,619
JardianceEmpagliflozin24$34,567
MounjaroTirzepatide29$30,335
Breo ElliptaFluticasone/Vilanterol33$23,728
RybelsusSemaglutide12$21,837
MyrbetriqMirabegron16$15,631
Lantus SolostarInsulin Glargine,hum.Rec.Anlog109$14,230
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$11,359
Spiriva RespimatTiotropium Bromide12$10,602
FarxigaDapagliflozin Propanediol15$10,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$258,757230 claims
Novo NordiskOzempic, Rybelsus$29$144,534105 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$13$81,706115 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$17$50,28547 claims
AstraZenecaFarxiga$44$10,37315 claims
Sanofi-aventis U.S. LLCLantus$13$5,98034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Brooksville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →